Movement Disorders Clinical Practice最新文献_第2页

Equal Distress and Less Hope in Parkinson's Disease Patients Compared to Brain Tumors Patients.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-12 DOI: 10.1002/mdc3.14355

Simone D'Souza, Esther Tekampe, Marco Skardelly, Stephan Zipfel, Martin Teufel, Björn Falkenburger

引用次数: 0

Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-11 DOI: 10.1002/mdc3.14345

Alagaratnam Niruban, Vaclav Dostal, Abigail Mutimer, Konstantinos Tsamis, Spyridon Kontaxis, Nicholas Kostikis, Foivos Kanellos, Adamantios Ntanis, George Rigas, Spyridon Konitsiotis

{"title":"Assessing Eligibility for Apomorphine Therapy in Parkinson's Disease: The Telemonitoring Potential.","authors":"Alagaratnam Niruban, Vaclav Dostal, Abigail Mutimer, Konstantinos Tsamis, Spyridon Kontaxis, Nicholas Kostikis, Foivos Kanellos, Adamantios Ntanis, George Rigas, Spyridon Konitsiotis","doi":"10.1002/mdc3.14345","DOIUrl":"https://doi.org/10.1002/mdc3.14345","url":null,"abstract":"Background: Although there are established guidelines for the selection of suitable candidates, objective and timely referral for the use of apomorphine remains challenging.Objectives: This research examined how telemonitoring may facilitate referrals for continuous subcutaneous apomorphine infusion in Parkinson's disease (PD).Methods: A Blind Rater and a multi-disciplinary team (MDT) including an expert PD nurse, neurologist, and geriatrician determined apomorphine pump treatment eligibility for 20 patients with PD. The MDT considered telemonitoring data and physical examination to determine eligibility. The Blind Rater used only telemonitoring data (PDMonitor®) to evaluate eligibility.Results: The results show that using wearable sensors to determine appropriateness of apomorphine pump treatment is similar to a complete method that combines objective motor symptom monitoring with clinical evaluation. The MDT and blind rater had a 0.89 Cohen's kappa coefficient, which suggests high rate of agreement. The best-performing objective metric for differentiating patients who were recommended (APO) from those non-recommended (non-APO) for apomorphine pump therapy, was the device-reported percentage of time in the \"ON\" state, which takes into consideration the \"OFF\" and dyskinesia time. The APO group had lower values in this metric and could be differentiated from the non-APO group accurately (85%).Conclusions: Using telemonitoring to determine eligibility for apomorphine therapy might improve evaluation and treatment in patients with PD and, therefore help improve their quality of life.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Posterior Subthalamic Area Deep Brain Stimulation Combined with Spinal Cord Stimulation in a Patient with Spinocerebellar Ataxia Type 12.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-10 DOI: 10.1002/mdc3.14356

Ruinan Shen, Zhuofan Zhou, Zhengyu Lin, Peng Huang, Yixin Pan, Dianyou Li, Yiwen Wu

引用次数: 0

Family with BCL11B Related Dystonia and Movement Disorders.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-10 DOI: 10.1002/mdc3.14357

Jaclyn M Martindale, Leah Chapman, Virginia Lane, Audrey Hunt, Jennifer E Harmon, Lia K Thibodaux, Lubna Jafri, Aubrey Hite, Jessica Tate, Linda Nicolotti, Michael S Okun

引用次数: 0

Improvement of Motor Function in SLC39A8-Related Ataxia Through Manganese Supplementation: A Therapeutic Insight.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-09 DOI: 10.1002/mdc3.70001

Denise Maria Meneses Cury Portela, Thiago Gonçalves Guimarães, Sandra Tuany Alves de Morais, Natália Rebeca Alves de Araújo, Luana Larisse de Sousa Araújo, Vinicius Santana Vasconcelos, Gustavo Sousa Noleto, Patricia Maria da Costa Braga, Sarah Teixeira Camargos

引用次数: 0

Prevalence of Parkinson's Disease in 22q11.2 Deletion Syndrome: A Multicenter Study.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-07 DOI: 10.1002/mdc3.14354

Emma N M M von Scheibler, Ann Swillen, Gabriela M Repetto, Nikolai Gil D Reyes, Anthony E Lang, Connie Marras, Mark L Kuijf, Rob P W Rouhl, Agnies M van Eeghen, Carlos Juri, Annick Vogels, Thérèse A M J van Amelsvoort, Anne S Bassett, Erik Boot

{"title":"Prevalence of Parkinson's Disease in 22q11.2 Deletion Syndrome: A Multicenter Study.","authors":"Emma N M M von Scheibler, Ann Swillen, Gabriela M Repetto, Nikolai Gil D Reyes, Anthony E Lang, Connie Marras, Mark L Kuijf, Rob P W Rouhl, Agnies M van Eeghen, Carlos Juri, Annick Vogels, Thérèse A M J van Amelsvoort, Anne S Bassett, Erik Boot","doi":"10.1002/mdc3.14354","DOIUrl":"https://doi.org/10.1002/mdc3.14354","url":null,"abstract":"Background: 22q11.2 deletion syndrome (22q11.2DS) has been associated with increased risk of early-onset Parkinson's disease (PD).Objective: To determine the prevalence and predictors of PD in a large international 22q11.2DS sample.Methods: The sample comprised 856 adults (median age 28 (range 16-76) years; 53.0% female). PD was defined as clinical diagnosis by a neurologist (including bradykinesia, rest tremor and/or rigidity). Age-specific risk and predictors of PD were analyzed using Kaplan-Meier curve and Cox regression.Results: PD was present in 1.8% (95% CI: 0.9-2.6%) of the sample, 3.4% (95% CI: 2.2-4.6%) when including uncertain PD (clinical diagnosis or suspicion, but not meeting all criteria), and 14.0% (95% CI: 6.9-21.0%) of those aged ≥50 years. Median age at motor onset was 45 (range 20-66) years. None of the factors considered were associated with PD.Conclusions: Given high PD prevalence and young onset, we propose periodic motor evaluations from age 40 years in 22q11.2DS.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Localization Matters: Impacts of PEG-J Localization in Intestinal Levodopa Therapy for Parkinson's Disease.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-04 DOI: 10.1002/mdc3.14352

Philipp Klocke, Moritz A Loeffler, Idil Cebi, Karl-Ernst Grund, Christine Daniels, Jens Volkmann, Jiri Koschel, Wolfgang H Jost, Kazimierz Logmin, Lars Wojtecki, Christoph R Werner, Daniel Weiss

{"title":"Localization Matters: Impacts of PEG-J Localization in Intestinal Levodopa Therapy for Parkinson's Disease.","authors":"Philipp Klocke, Moritz A Loeffler, Idil Cebi, Karl-Ernst Grund, Christine Daniels, Jens Volkmann, Jiri Koschel, Wolfgang H Jost, Kazimierz Logmin, Lars Wojtecki, Christoph R Werner, Daniel Weiss","doi":"10.1002/mdc3.14352","DOIUrl":"https://doi.org/10.1002/mdc3.14352","url":null,"abstract":"Background: Real-world clinical evidence is missing to understand the resorption characteristics of levodopa through duodenal and jejunal parts of the small intestine.Objective: To characterize how different application sites of intestinal levodopa gel would impact on levodopa dosing and clinical outcomes.Methods: This multicentre retrospective analysis investigated Parkinson's disease patients (n = 111) and their change in levodopa equivalent dosage when switching from oral treatment to intestinal continuous infusion therapy while stratifying for differences in percutaneous gastrojejunostomy (PEG-J) tube localizations. We analyzed data from patients treated with both levodopa-carbidopa (LCIG) and levodopa-carbidopa-entacapone (LECIG) intestinal gel.Results: In dichotomic analysis, duodenal and jejunal tube positions showed similar levodopa equivalent dosages changes from baseline (P = 0.143). This was similar when subdividing patients for LCIG and LECIG treatment. In duodenal PEG-J positions, 44.4% of patients showed persistent motor fluctuations compared to 21.9% in jejunal placements (P = 0.026). In duodenal positions, fluctuations most often persisted when the PEG-J tube was placed proximally into the duodenum. In jejunal localizations, several patients displayed a satisfactory outcome from the primary intervention but experienced dislocation of the PEG-J tube to a duodenal position. This was associated with re-emergence of motor fluctuations in a majority of them.Conclusions: Our real-world data suggest that LCIG and LECIG are absorbed similarly in both duodenal and jejunal portions of the small intestine. However, clinical data suggest, that jejunal positioning is critical to the stabilization of dopaminergic motor fluctuations.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimodality Brain Imaging Markers in Progressive Supranuclear Palsy Subtypes and Parkinson's Disease.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-04 DOI: 10.1002/mdc3.14346

Kanchana Soman Pillai, Parvathy Rajeswari, Ravindra B Kamble, Shagos Gopalan Nair Santhamma, Manas Chacko, Vijay Jayakrishnan, Ranjini Ramachandran, Ayana Avarachan, Asha Kishore

{"title":"Multimodality Brain Imaging Markers in Progressive Supranuclear Palsy Subtypes and Parkinson's Disease.","authors":"Kanchana Soman Pillai, Parvathy Rajeswari, Ravindra B Kamble, Shagos Gopalan Nair Santhamma, Manas Chacko, Vijay Jayakrishnan, Ranjini Ramachandran, Ayana Avarachan, Asha Kishore","doi":"10.1002/mdc3.14346","DOIUrl":"https://doi.org/10.1002/mdc3.14346","url":null,"abstract":"Background: The new classification of progressive supranuclear palsy (PSP) subtypes necessitates identifying radiological biomarkers to support the clinical diagnosis.Objective: The goals was to test if magnetic resonance imaging (MRI) morphometry, diffusion tensor imaging (DTI), susceptibility-weighted imaging (SWI), or [18F]fluorodeoxyglucose (18FFDG)-positron emission tomography (PET) differentiates PSP subtypes from each other or Parkinson's disease (PD).Methods: Midbrain/pons (M/P) area ratio, middle/superior cerebellar peduncle (MCP/SCP) width ratio, magnetic resonance parkinsonism indices (MRPI and MRPI2) and midbrain antero-posterior (AP) diameter were measured. Region of interest-based DTI, SWI, and 18FFDG-PET analyses were performed.Results: Four PSP subtypes (n = 85) and 24 PD were studied. MRI morphometry and DTI could differentiate PSP-Richardson syndrome (PSP-RS) from PSP-parkinsonism, PSP-postural instability, and PD (area under curve >0.7). SWI did not differentiate among PSP subtypes or PD. 18FFDG-PET distinguished PSP from PD.Conclusions: MRI morphometry and DTI differentiated PSP-RS from the other common PSP subtypes and PD and may be tested as a radiological marker of PSP-RS in larger studies.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Unusual Presentation of a DNMT1 Mutation: Progressive Supranuclear Palsy Look-Alike Disorder.

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-03 DOI: 10.1002/mdc3.14344

Milica Ječmenica Lukić, Andona Milovanović, Nina Mazalica, Ana Westenberger, Aleksandra Tomić Pešić, Igor Petrović, Vladana Marković, Nikola Kresojević, Christine Klein, Vladimir S Kostić, Nataša Dragašević-Mišković

引用次数: 0

Entrainment Characteristics of Functional Tremor. 功能性震颤的诱导特征

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-01 Epub Date: 2024-11-04 DOI: 10.1002/mdc3.14258

Aditya Murgai, Svetlana Iskhakova

引用次数: 0